<code id='1AFA5B386B'></code><style id='1AFA5B386B'></style>
    • <acronym id='1AFA5B386B'></acronym>
      <center id='1AFA5B386B'><center id='1AFA5B386B'><tfoot id='1AFA5B386B'></tfoot></center><abbr id='1AFA5B386B'><dir id='1AFA5B386B'><tfoot id='1AFA5B386B'></tfoot><noframes id='1AFA5B386B'>

    • <optgroup id='1AFA5B386B'><strike id='1AFA5B386B'><sup id='1AFA5B386B'></sup></strike><code id='1AFA5B386B'></code></optgroup>
        1. <b id='1AFA5B386B'><label id='1AFA5B386B'><select id='1AFA5B386B'><dt id='1AFA5B386B'><span id='1AFA5B386B'></span></dt></select></label></b><u id='1AFA5B386B'></u>
          <i id='1AFA5B386B'><strike id='1AFA5B386B'><tt id='1AFA5B386B'><pre id='1AFA5B386B'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:782
          Chemotherapy infusion
          The White House outlined its efforts to end shortages of three key generic chemotherapies. But experts want more more details. Gerry Broome/AP

          WASHINGTON — The White House says it’s working to end shortages of three key generic chemotherapies. But experts said the administration would have to provide more details to fully mitigate the health care system’s concerns.

          Carboplatin, cisplatin, and methotrexate are three of 15 cancer drugs in shortage in the United States. They have been staples of cancer treatment for decades, according to a White House blog post, but their supply in the United States has been nearly halved in the past year. The shortages have forced doctors to ration the drugs and alter treatment plans, leaving cancer patients to wonder whether their survival odds are hurt.

          advertisement

          In its blog post, the White House noted that it’s now allowing Chinese imports of cisplatin. The Food and Drug Administration is also working with generic drug companies to boost production of all three drugs, but it didn’t say which companies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry
          Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

          GwenPetersen,38,anALSpatient,believesthattherecentfailureofAmylyx'sdrugRelyvriocouldstillteachresear

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

          SammyKimballforSTATCanbiotechstartupssurviveadownturn?IsCovid-19agoodbusiness?Andwhendidophthalmolog